Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation

Clin Lung Cancer. 2020 Jul;21(4):e258-e260. doi: 10.1016/j.cllc.2019.12.002. Epub 2020 Jan 23.
No abstract available

Keywords: Concomitant mutation; EGFR L858R; KRAS; Loss of T790M.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acrylamides / pharmacology*
  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / genetics
  • Adenocarcinoma of Lung / pathology
  • Afatinib / therapeutic use*
  • Aged
  • Aniline Compounds / pharmacology*
  • Antineoplastic Agents / therapeutic use*
  • Drug Resistance, Neoplasm / drug effects*
  • Drug Resistance, Neoplasm / genetics
  • ErbB Receptors / genetics
  • Female
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Mutation*
  • Prognosis

Substances

  • Acrylamides
  • Aniline Compounds
  • Antineoplastic Agents
  • osimertinib
  • Afatinib
  • EGFR protein, human
  • ErbB Receptors